Global Bronchial Carcinoid Market – Industry Trends and Forecast to 2029

Bronchial Carcinoid Market Analysis and Size

The global bronchial carcinoid market is expected to witness significant growth during the forecast period. Carcinoid tumor is a rare type of malignant disorder that accumulates for less than 1% of all malignant disorders. About 2 to 4 out of 10 carcinoid tumors are found in the lungs. The cause of lung carcinoid tumors is still unknown. Growing cases of carcinoid tumors, mucoepidermoid carcinoma and family history with lung disorders drives the bronchial carcinoid market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global bronchial carcinoid market  in the forecast period 2022-2029. The global bronchial carcinoid market  is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bronchial Carcinoid Market Scope and Segmentation

Market Definition

Bronchial carcinoid is uncommon, rare disorder that affects 1 to 2% of all lung cancers in adults. It is a slow growing neuroendocrine tumors and low-grade malignant neoplasms rising from bronchial mucosa. Central bronchial carcinoids are common compared to the peripheral and produces symptoms including bronchial obstruction such as cough, localized wheeze, non-resolving recurrent pneumonitis, chest pain, and fever. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Bronchial Carcinoid Market Dynamics

Drivers

• Increase in Lung Cancer

According to the GLOBOCAN 2020 estimates by the International Agency for Research on Cancer, about 19.3 million new cases of cancer recorded in 2020 and around 11.4% of them were lung cancer. Lung cancer was the primary cause of death with about 18% or 1.8 million global deaths in 2020. Thus this increasing lung cancer result in the origin of bronchial carcinoid and in return this boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global bronchial carcinoid market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increase in Geriatric Population

The elderly population is projected to increase the patient population worldwide, which boots the market in the forecast period. As per the reports of WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The range of possibility of getting infected with varied types of cancer also rises. This boost the market growth.

• Higher Indulgence of  Advanced Therapies

The rapid growth of the biopharmaceutical industry and the increasing R&D expenses have resulted in the development of several advanced targeted therapeutics to treat lung cancer. The targeted therapy can efficiently treat cancer cells without altering the body's normal cells. This results in nominal side-effects and removes the chances of reoccurrence and deaths. The rising healthcare expenditure combined with the rising awareness associated with the availability of advanced gene therapies that can cure traditionally non-curable diseases has significantly boosted the growth of the targeted therapy across the globe. This creates more opportunities in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global bronchial carcinoid market over a forecast period.

• High Cost

The huge expenditure of the treatment methods such as radiation therapy, chemotherapy, medications are hamper the market growth.

This global bronchial carcinoid market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global bronchial carcinoid market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Bronchial Carcinoid Market Scope

The global bronchial carcinoid market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Central Bronchial Carcinoids
• Peripheral Bronchial Carcinoids
• Others

Treatment Type

• Surgery
• Radiation Therapy
• Chemotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Bronchial Carcinoid Market Regional Analysis/Insights

The global bronchial carcinoid market  is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global bronchial carcinoid market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to presence of advanced technology and high R&D & healthcare expenditure.

Asia-Pacific dominates the market due to growing geriatric population suffering from lung disorder, increased usage of cigarettes & alcohol and presence of generic manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Bronchial Carcinoid Market Share Analysis

The global bronchial carcinoid market competitive landscape provides details by competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global bronchial carcinoid market.

Key players operating in the global bronchial carcinoid market  include:

• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• NATCO Pharma Limited (India)
• Shilpa Therapeutics Private Ltd. (India)

SKU-54193